803 related articles for article (PubMed ID: 15041473)
21. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig.
Johnson WB; Katugampola S; Able S; Napier C; Harding SE
Life Sci; 2012 Feb; 90(9-10):328-36. PubMed ID: 22261303
[TBL] [Abstract][Full Text] [Related]
22. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.
Zhang W; Colman RW
Blood; 2007 Sep; 110(5):1475-82. PubMed ID: 17392505
[TBL] [Abstract][Full Text] [Related]
23. [Kinetic properties and regulation of cyclic nucleotide phosphodiesterases in lymphoid cells].
Azhaeva EV; Severin ES
Bioorg Khim; 1987 Sep; 13(9):1157-63. PubMed ID: 2827690
[TBL] [Abstract][Full Text] [Related]
24. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.
Kerfant BG; Zhao D; Lorenzen-Schmidt I; Wilson LS; Cai S; Chen SR; Maurice DH; Backx PH
Circ Res; 2007 Aug; 101(4):400-8. PubMed ID: 17615371
[TBL] [Abstract][Full Text] [Related]
25. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.
Pauvert O; Lugnier C; Keravis T; Marthan R; Rousseau E; Savineau JP
Br J Pharmacol; 2003 Jun; 139(3):513-22. PubMed ID: 12788811
[TBL] [Abstract][Full Text] [Related]
26. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
27. [Phosphodiesterases of cyclic GMP].
Wróblewska H; Gorczyca WA
Postepy Hig Med Dosw; 2001; 55(5):611-27. PubMed ID: 11795198
[TBL] [Abstract][Full Text] [Related]
28. Changes in phosphodiesterase activity in the developing rat submandibular gland.
Tanaka S; Shimooka S; Shimomura H
Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
[TBL] [Abstract][Full Text] [Related]
29. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.
Dickinson NT; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):371-7. PubMed ID: 9163326
[TBL] [Abstract][Full Text] [Related]
30. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function.
Aszódi A; Pfeifer A; Ahmad M; Glauner M; Zhou XH; Ny L; Andersson KE; Kehrel B; Offermanns S; Fässler R
EMBO J; 1999 Jan; 18(1):37-48. PubMed ID: 9878048
[TBL] [Abstract][Full Text] [Related]
31. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
[TBL] [Abstract][Full Text] [Related]
32. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
[TBL] [Abstract][Full Text] [Related]
33. [Cyclic AMP-specific nucleotide phosphodiesterase from the insoluble fraction of the human brain].
Kireeva NN; Bobruskin ID; Severin SE
Biokhimiia; 1995 May; 60(5):694-708. PubMed ID: 7662796
[TBL] [Abstract][Full Text] [Related]
34. New insight into the role of phosphodiesterase 3A in porcine oocyte maturation.
Sasseville M; Côté N; Guillemette C; Richard FJ
BMC Dev Biol; 2006 Oct; 6():47. PubMed ID: 17038172
[TBL] [Abstract][Full Text] [Related]
35. 2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.
Benjamin CW; Lin AH; Morris J; Wishka DG; Gorman RR
J Pharmacol Exp Ther; 1993 Apr; 265(1):457-62. PubMed ID: 7682615
[TBL] [Abstract][Full Text] [Related]
36. Altered role of C-type natriuretic peptide-activated pGC-cGMP-PDE3-cAMP signaling in hyperthyroid beating rabbit atria.
Wen JF; Quan HX; Zhou GH; Cho KW
Regul Pept; 2007 Aug; 142(3):123-30. PubMed ID: 17531330
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide-induced changes in endothelial expression of phosphodiesterases 2, 3, and 5.
Schankin CJ; Kruse LS; Reinisch VM; Jungmann S; Kristensen JC; Grau S; Ferrari U; Sinicina I; Goldbrunner R; Straube A; Kruuse C
Headache; 2010 Mar; 50(3):431-41. PubMed ID: 19751368
[TBL] [Abstract][Full Text] [Related]
38. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
39. A new cGMP phosphodiesterase isolated from bovine platelets is substrate for cAMP- and cGMP-dependent protein kinases: evidence for a key role in the process of platelet activation.
Robichon A
J Cell Biochem; 1991 Oct; 47(2):147-57. PubMed ID: 1661738
[TBL] [Abstract][Full Text] [Related]
40. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
